key: cord-0800350-hoqny67n
authors: Regelmann, Molly O.; Conroy, Rushika; Gourgari, Evgenia; Gupta, Anshu; Guttmann-Bauman, Ines; Heksch, Ryan; Kamboj, Manmohan K.; Krishnan, Sowmya; Lahoti, Amit; Matlock, Kristal
title: Pediatric Endocrinology in the Time of COVID-19: Considerations for the Rapid Implementation of Telemedicine and Management of Pediatric Endocrine Conditions
date: 2021-01-22
journal: Horm Res Paediatr
DOI: 10.1159/000513060
sha: 5ebe0022a2513d85e8e0ffe55f125097d8e0d2af
doc_id: 800350
cord_uid: hoqny67n

BACKGROUND: Pediatric endocrine practices had to rapidly transition to telemedicine care at the onset of the novel coronavirus disease 2019 (COVID-19) pandemic. For many, it was an abrupt introduction to providing virtual healthcare, with concerns related to quality of patient care, patient privacy, productivity, and compensation, as workflows had to change. SUMMARY: The review summarizes the common adaptations for telemedicine during the pandemic with respect to the practice of pediatric endocrinology and discusses the benefits and potential barriers to telemedicine. KEY MESSAGES: With adjustments to practice, telemedicine has allowed providers to deliver care to their patients during the COVID-19 pandemic. The broader implementation of telemedicine in pediatric endocrinology practice has the potential for expanding patient access. Research assessing the impact of telemedicine on patient care outcomes in those with pediatric endocrinology conditions will be necessary to justify its continued use beyond the COVID-19 pandemic.

Until recently, in the USA, telemedicine has had lim ited applications due to lack of payer acceptance. With the onset of the novel coronavirus disease 2019 (CO DOI: 10 .1159/000513060 VID19) pandemic, many pediatric endocrine practices have been forced to rapidly transition to virtual visits; this served as a practical solution to reduce risks for infection by allowing patients and families to access care from their homes. The implementation of telemedicine has led to positive experiences and acceptance by many patients, families, and providers. Telemedicine reduces costs of transportation, time missed from work and school, and anxiety felt by patients and families because they are seen in their familiar home environment [1] [2] [3] . Following the COVID19 pandemic, it seems likely that telemedicine will be permanently integrated into clinical practice [1, 4] . Most providers in the pediatric endocrinology commu nity have experience reviewing blood glucose logs for di abetes over the phone or via patient portals, but many have limited experience with remote physical examina tions and best practices for telemedicine. Even those who previously utilized video telemedicine prior to the pan demic had to adjust to patients being at their home, rath er than in clinics with trained medical professionals avail able to obtain vital signs and anthropometric measure ments. There are limited data to provide evidence for best practices with respect to telemedicine and the practice of pediatric endocrinology. We aim to summarize the con siderations related to the broader implementation of tele medicine into pediatric endocrine practices and provide our expert opinion regarding processes for providing pa tient care.

Effective implementation and reimbursement for telemedicine require Health Insurance Portability and Accountability Act (HIPAA)compliant platforms (in the USA, HIPAA ensures the security of private patient medical information), availability of technology for pro viders and patients, and an understanding of payer re quirements. The Centers for Medicare and Medicaid Ser vices (CMS) issued an interim final rule on March 30, 2020, that extends temporary regulatory waivers to healthcare providers to facilitate safe and effective care; however, the duration of the waivers is unclear. The reg ulations aimed to increase hospital capacity, expand the healthcare workforce, improve access to telehealth ser vices, and reduce the regulatory burden on providers. These regulations became retroactively applicable begin ning on March 1, 2020. Although these changes are ac cepted by Medicare, private insurers are not mandated to adopt them. Areas relevant to endocrine practices in clude the following: − Expansion of covered telehealth services − Reducing or waiving beneficiary costsharing for tele health and certain other services − Coverage of remote monitoring services for new pa tients − Coverage of telephone evaluation and management (E/M) services − Waiving of the requirement for the facetoface visit for patients with insulin pumps − Simplification of the documentation requirements for E/M services delivered via telehealth − Provision of additional flexibility to deliver Medicare Diabetes Prevention Program services [5] Telehealth implementation requires a comprehensive understanding of eligibility, terminology, and billing. It is important to be aware of state and institutionspecific licensing requirements prior to implementation, as well as both insurance and malpractice coverage of the visits. Eligibility and documentation requirements differ for telemedicine visits according to their classification. Un derstanding of the requirements is essential for compli ance with coding and billing. Virtual services include tele health visits, virtual checkins, and evisits [6] . Until the COVID19 pandemic, state medical licensure regulations limited some telehealth services that crossed state lines and included requirements for endtoend HIPAAcom pliant hardware and software. Historically, providers had to be licensed in the state the patient was in at the time of the visit, at least for new patient consultations. With the onset of the pandemic, CMS waived this requirement for Medicare patients. States could request a waiver for Med icaid patients, and the Department of Health and Human Services has requested states to modify licensure require ments to facilitate interstate practice, although this has only occurred to a limited degree. Because rules are changing quickly and may revert once the pandemic re solves, it will be important to remain informed and adjust practices accordingly [7] (Table 1) .

Telemedicine encounters also require patients and families to have the resources to allow for successful visits. The introduction of telehealth has brought to the fore front concerns about patient privacy and security of com munication platforms. HIPAA violation penalties against healthcare workers have been waived temporarily to al low for use of widely available videocalling services, such as FaceTime ® , Skype ® , Google Duo ® , and WhatsApp ® , but institutions appropriately continue to encourage use of HIPAAcompliant platforms, for example, Zoom Table 2 highlights practical considerations for telemedicine visits.

The COVID19 pandemic has presented unique chal lenges in the care of pediatric patients with diabetes in the inpatient setting, outpatient clinics, and in the application of current screening recommendations for ongoing care.

For patients with newonset diabetes mellitus, espe cially those presenting in diabetic ketoacidosis (DKA) or in institutions where all newonset diabetes education is done in an inpatient setting, teams faced several barriers with respect to safety, access, and patientcenteredness [8, a Length of visit is used based on counseling, discussion, and/or coordination of care being >50% of the visit. Visits may also be billed based on complexity. Table modified from Smith et al. [6] , with permission from Elsevier. 9] . Often the inpatient teams comprised multiple mem bers, including but not limited to trainees, nurses, diabe tes educators, dietitians, and social workers, thus increas ing exposure to and from multiple personnel. One of the initial modifications for familycentered team rounds has been to limit the number of team members entering the patient's room. Aside from the initial history, physical ex amination, and initial discussion with the endocrinolo gists, the roles of the diabetes care team, which includes diabetes educators, dietitians, and social workers, typi cally involve prolonged facetoface education and dis cussion time. These processes are more complex to mod ify and often rely on individual institutional guidelines. The use of video platforms to complete some of the tasks has been implemented at many institutions, although some do not allow telehealth for inpatient care, and the efficacy of telemedicine for newonset diabetes education is unknown at this time.

Restrictions on the number of family members (often only one caregiver) allowed with each child either admit ted to the hospital or visiting the clinic further complicate care and discharge planning. Diabetes education most of ten is a "family affair"; multiple family members and care givers typically require diabetes education in order to care for the child. Consequently, a limitation on the number of visitors requires additional time for diabetes team members to set up virtual or outpatient clinic trainings. Hospital and clinicissued tablets and virtual meetings have been used by physicians and diabetes team members to connect to other family members while providing in patient facetoface diabetes education [9, 10] . Finally, the use of continuous glucose monitors (CGM) in the in patient setting has been recognized as an alternative to reduce the time spent with patients during the COVID19 pandemic [11, 12] . However, the safe implementation of CGM systems in the inpatient setting might be challeng ing and requires the creation of CGM protocols by hos pitals and availability of trained personnel [12] .

Remote monitoring technologies such as wireless standalone glucose meters, CGM, and insulin pumps in tegrated with CGM can transmit data via a cloudbased platform to a website, a patient's smart phone, or to a pro vider's clinic [13, 14] . During the pandemic, these tech nologies have played a central role in ensuring access to remote healthcare for children with diabetes [8, 14, 15] . Simultaneously, the technology has brought forth chal lenges with respect to the remote training of patients and caregivers and led to new processes for communication with patients, which require consideration for data pri vacy and confidentiality. In addition, clinic workflow has had to change to account for the transition from inper son glucose meter, CGM, and insulin pump downloads to telehealth uploads [8, 14] .

In an ideal setting, centers with a dedicated diabetes clinic can have staff (e.g., medical assistants, nurses, and diabetes educators) assume the role of connecting and transmitting patient data to the provider prior to and af ter an appointment. As an example of a process followed by some centers, patients were contacted by the clinic team member to check if they had a device compatible with software, such as Dexcom Clarity ® , Glooko/Dia send ® , Medtronic CareLink ® , t:connect ® , and Tide pool ® . Clinic staff provided technological support to pa tients who had a device that was not yet synchronized with the clinic. Approximately 2 business days before the visit, the patient is instructed to "upload" or "synchro nize" their device. The data are then downloaded by the diabetes support staff, and the report was incorporated into the patient's chart. Patients who use an independent application or a noncloud compatible device are in structed on how to download a report and send to clinic by various methods, including an electronic secure portal for enrolled patients and fax/email for others. For pa tients with limited English proficiency and/or no access to the above mentioned resources, the diabetes educators obtain data via phone for a 3-5day period and provide that via a "logbook" to the provider. In centers utilizing a shared model of staffing or providers in solo practice, there is a significant variation in delegation of this sup port role and often the burden for obtaining records falls on the provider. Availability of training in these technol ogies for ancillary staff and patients is vital to sustaining remote monitoring programs for diabetes during and af ter the pandemic [13, 16, 17] . Integration of remote mon itoring technology into modern electronic health records may help mitigate privacy and confidentiality concerns over transmission of data via nonHIPAA approved mo dalities, such as email.

Telemedicine visits for pediatric and adolescent pa tients with diabetes pose several specific challenges, but also can provide an opportunity for providers to better understand social concerns in patients' home environ ments. Anecdotally, adolescent patients may be more open to engaging with video technology, although ensur ing their privacy during interviewing may be more diffi cult. Sending questionnaires, such as a depression screen, either through a secure patient portal or email prior to the visit may help facilitate visits, but safety procedures Horm Res Paediatr 2020;93:343-350 DOI: 10.1159/000513060 need to be put in place to ensure timely followup of con cerning responses [18] . Home medications and supplies can be checked via video. Teaching handson skills, such as injections and glucose monitoring, may be more dif ficult without a provider's hand to guide the patient and caregiver. Physical examinations specifically to assess for neuropathy and lipohypertrophy at insulin injection sites, as well as pubertal examinations and blood pressure monitoring (see discussions below), are also likely to be limited by telehealth capabilities and should be priori tized when patients are evaluated during inperson visits.

Diabetic Retinopathy Screening For those with type 1 diabetes mellitus, the American Diabetes Association (ADA) recommends that after the initial screening (recommended at age 10 years or after puberty, whichever occurs earlier, in patients younger than 18 years with diabetes for 3-5 years), repeat exami nations for diabetic retinopathy are recommended annu ally, but at the discretion of an eye care professional, it may be reasonable to check every 2 years [19] . The Inter national Society for Pediatric and Adolescent Diabetes (ISPAD) recommends screening for retinopathy starting from 11 years with a diabetes duration of 2-5 years. The ISPAD guidelines also support retinal exams every other year in those with diabetes for <10 years and without risk factors (risk factors were defined as poor diabetes control, high blood pressure, dyslipidemia, and high body mass index) [20] . Screening is recommended at diagnosis and annually for those with type 2 diabetes [19, 20] . Digital retinal exams by telemedicine have been used to evaluate adults for diabetic retinopathy and could be a costeffec tive alternative in youth with diabetes, but still require access to the technology to image the retina [21] . Some evidence suggests frequent eye examinations might not be universally necessary in youth <18 years of age; thus, in the setting of a pandemic, it may be reasonable to con sider deferring the routine screening examination until local infection rates are sufficiently low [22] .

The ADA and the American Academy of Pediatrics recommend screening youth with diabetes for hyperten sion at every visit [19, 23, 24] . ISPAD guidelines recom mend blood pressure monitoring "at least annually" [20] . Telemedicine has been used for remote monitoring of home blood pressure with the use of certain devices, but their utility to screen asymptomatic youth with diabetes is unclear [25] . Ambulatory 24h remote blood pressure monitoring could be used to screen for hypertension in youth with diabetes mellitus at high risk for cardiovascu lar disease. Other options include inperson dropin visits to obtain blood pressure along with anthropometric data that can be evaluated during the virtual visit, but this pro cess still requires staff and time to clean equipment for infection control.

Blood and Urine Screening For patients using CGM, the Glucose Management In dicator is an acceptable alternative to hemoglobin A1c (HbA1c) that can provide information for personalized diabetes management [26] . In a pandemic setting, HbA1c would be more helpful for children who are not adherent with blood glucose monitoring and are not using CGM. Screening tests for celiac disease, thyroid dysfunction, and hyperlipidemia could also be deferred in children who had a normal examination in the last 2 years and continue to be asymptomatic [19] . ADA guidelines rec ommend annual assessment of urine albumin/creatinine ratios in youth who have had type 1 diabetes for at least 5 years and are either pubertal or >10 years of age, which ever is earlier [19] . ISPAD guidelines suggest screening for albuminuria starting at age 11 years in those with a diabetes duration of 2-5 years [20] . A urine albumin/cre atinine ratio test is recommended at diagnosis and annu ally for those with type 2 diabetes mellitus [19, 20, 27] .

Comprehensive assessment of pediatric endocrine conditions requires evaluation of anthropometrics and laboratory/radiologic assessments in addition to detailed histories and physical examinations. Prior studies show successful use of telemedicine for pediatric obesity, but it can be challenging to translate this process into telemed icine for other endocrine conditions [28] [29] [30] . Requesting growth charts from the referring provider along with or dering targeted laboratory and radiologic assessment pri or to the visit assists in efficient use of telemedicine and in triaging those who require inperson evaluation. This requires education of scheduling personnel and clinical staff on recommended protocols, identification of local laboratory facilities, urgency of evaluation, and required information to appropriately evaluate each condition. For example, when evaluating a child with concerns for hyperthyroidism, obtaining prior thyroid function tests, vital signs from a recent visit to the referring provider, and directing patients to have any additional laboratory DOI: 10.1159/000513060 testing prior to the visit can drastically improve the effi ciency of a telemedicine visit.

Clinicians can also utilize techniques to improve phys ical assessment during visits. Parentmeasured height and weight is an alternative when inoffice measurements are not feasible; parents can be provided with instructions on how to obtain measurements to streamline this pro cess [31, 32] . Pubertal and genital examinations via video are not recommended. Pubertal examinations present a significant challenge; a recent metaanalysis found self assessment of puberty is most accurate when identifying Tanner stage 1 for pubic hair for both sexes, Tanner stage 1 for breast development, and Tanner stage 5 for male pubic hair. Accuracy was diminished for the stages inbe tween [33, 34] . Families may have access to a blood pres sure monitor and could measure heart rate manually or via home device if prompted. In addition, diseasespecif ic symptom checklists can be created in the EMR and completed by families prior to their visit to streamline the process.

During telemedicine visits, historytaking remains es sentially unchanged compared to inperson encounters. However, sensitive information (i.e., drug use, libido, and sexual history) may be difficult to acquire confidentially. Establishing a routine for adolescents to have a few min utes to answer confidential questions alone in the room may help. At the provider's discretion, an inperson visit should be requested for a focused examination when eval uating a thyroid nodule, assessing pubertal stage, clitoral size, genitourinary anomalies, and other findings that cannot be effectively assessed virtually. Table 3 details op portunities and challenges in the management and evalu ation of common endocrine conditions when access to inperson visits is limited.

Telemedicine has been an essential tool during the COVID19 pandemic, as it has allowed providers to de liver care to their patients, albeit with some compromises and adjustments. The broad implementation of telemed icine has the potential for expanding access to care and improvement in the management of chronic conditions. Lessons learned during the pandemic should be used as the first step to address the longterm use of telemedicine practices in specific, welldefined scenarios. Research as sessing the impact of telemedicine on the care of pediatric endocrinology conditions will be necessary to justify its continued use beyond the COVID19 pandemic [15] . In stitutional policies and procedures will need to be updat ed to address patient privacy and provider workflow as telemedicine is likely to remain part of pediatric endo crine care. Finally, continued adequate payer reimburse ment for care coordination and remote monitoring will be necessary in order to assure longterm viability of tele medicine practices in pediatric endocrinology.

Telemedicine: pediatric applications

Family perspectives on telemedi cine for pediatric subspecialty care

Telehealth per ceptions in patients with epilepsy and provid ers during the COVID19 pandemic

Will tele medicine be the Blockbuster or Netflix of healthcare? Medpage Today

Hormone Science to Health, document pre pared for the Endocrine Society by Cavaroc chi Ruscio Dennis Associates

Implementation guide for rapid integration of an outpatient telemedi cine program during the COVID19 pan demic

Coding in the world of COVID19: nonfacetoface evaluation and management care. Continu um

Managing newonset type 1 diabetes during the COVID19 pandemic: challenges and op portunities

Inpatient transition to virtual care during COVID19 pandemic. Di abetes Technol Ther

The silver lining to CO VID19: avoiding diabetic ketoacidosis ad missions with telehealth

Reducing inpa tient hypoglycemia in the general wards using realtime continuous glucose monitoring: the glucose telemetry system. a randomized clini cal trial. Diabetes Care

A pragmatic approach to inpatient diabetes management during the COVID19 pandem ic

The digital/vir tual diabetes clinic: the future is nonrecom mendations from an international panel on diabetes digital technologies introduction

A systematic review of pediatric telediabetes service models

Car ing for children and adolescents with type 1 diabetes mellitus: Italian Society for Pediatric Endocrinology and Diabetology (ISPED) statements during COVID19 pandemia. Di abetes Res Clin Pract

Success factors in the longterm sustainability of a telediabetes pro gramme

Diabetes manage ment through remote patient monitoring: the importance of patient activation and engage ment with the technology

Using telemedicine to reach ado lescents during the COVID19 pandemic

Children and adolescents: standards of medical care in diabetes2020. Diabetes Care

ISPAD clinical practice consensus guidelines 2018: microvascular and macrovascular com plications in children and adolescents

Costeffectiveness of diabetic ret inopathy screening programs using telemedi cine: a systematic review. Cost Eff Resour Al loc

Screening eye exams in youth with type 1 diabetes under 18 years of age: once may be enough? Pediatr Di abetes

Sub committee on screening management of high blood pressure in children. Clinical practice guideline for screening and management of high blood pressure in children and adoles cents

Cardio vascular risk reduction in highrisk pediatric patients: a scientific statement from the American Heart Association

The role of telemedicine in hypertension management: focus on blood pressure telemonitoring

Glucose management indicator (GMI): a new term for estimating A1C from continuous glucose monitoring

ISPAD clinical practice consensus guidelines 2018: type 2 di abetes mellitus in youth

Treating rural paedi atric obesity through telemedicine vs. tele phone: outcomes from a cluster randomized controlled trial

The use of TeleMedicine in the treatment of paediatric obesity: feasibility and acceptability. Matern Child Nutr

Longterm treatment of obese children and adolescents using a telemedicine support programme

Accuracy of parentmeasured and parentestimated heights and weights in determining child weight status

Center for Disease Control Public Health Me dia Library

Measuring Children's Height and Weight Accurately At Home

Can we rely on adolescents to selfassess puberty stage? A systematic review and metaanalysis

Validity of selfassessment of pubertal maturation

Thyroid cancer: possible role of telemedicine. Acta Otorhino laryngol Ital

Assays for thyroidstimulating hormone using dried blood spotted filter paper speci mens to screen for hypothyroidism in older children and adults

American Association of Clinical Endocri nologists, American College of Endocrinolo gy, and Androgen Excess and PCOS Society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome: part 2

Curr Probl Pediatr Adolesc Health Care

Inhibin B, AMH, but not INSL3, IGF1 or DHEAS support differentiation be tween constitutional delay of growth and pu berty and hypogonadotropic hypogonadism

Clinical review: distinguishing constitutional delay of growth and puberty from isolated hypogonadotropic hypogonadism: critical appraisal of available diagnostic tests

Recent advances in the understanding and management of delayed puberty

A single histrelin implant is effective for 2 years for treatment of central precocious pu berty

The diagnostic work up of growth failure in secondary health care; an evaluation of consensus guidelines. BMC Pe diatr

Endocrine treatment of genderdysphoric/ genderincongruent persons: an Endocrine Society clinical practice guideline

Congenital ad renal hyperplasia due to steroid 21hydroxy lase deficiency: an Endocrine Society clinical practice guideline

The authors thank the members of the Board of Directors and the larger Drug and Therapeutics Committee and Practice Man agement Committee of the Pediatric Endocrine Society for thoughtful review and constructive comments of the manuscript.

The authors have no conflicts of interest to declare.

Support of this publication was provided by the Pediatric En docrine Society.

The concept for the manuscript was discussed as part of a larg er Drug and Therapeutics Committee meeting. M.R. formally pro posed the concept to the Board of Directors of the Pediatric Endo crine Society. All listed authors participated in a discussion of the outline of the manuscript, contributed original sections of text and/or tables of the initial draft, and provided review and edits of subsequent drafts. M.R. prepared the final manuscript. All the list ed authors read and approved the final manuscript. The Drug and Therapeutics Committee and the Practice Management Commit tee, as well as the Board of Directors of the Pediatric Endocrine Society, had the opportunity to review and comment on the man uscript.